- Home
- ANTA vs CLLS Comparison
ANTA vs CLLS Comparison
Compare ANTA & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTA
- CLLS
- Stock Information
- Founded
- ANTA 2022
- CLLS 1999
- Country
- ANTA Singapore
- CLLS France
- Employees
- ANTA N/A
- CLLS N/A
- Industry
- ANTA Investment Bankers/Brokers/Service
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- ANTA Finance
- CLLS Health Care
- Exchange
- ANTA Nasdaq
- CLLS Nasdaq
- Market Cap
- ANTA 291.0M
- CLLS 299.0M
- IPO Year
- ANTA 2025
- CLLS 2007
- Fundamental
- Price
- ANTA $9.92
- CLLS $4.12
- Analyst Decision
- ANTA Strong Buy
- CLLS Buy
- Analyst Count
- ANTA 3
- CLLS 1
- Target Price
- ANTA $17.50
- CLLS $8.00
- AVG Volume (30 Days)
- ANTA 8.2K
- CLLS 79.0K
- Earning Date
- ANTA 11-10-2025
- CLLS 11-07-2025
- Dividend Yield
- ANTA N/A
- CLLS N/A
- EPS Growth
- ANTA 669.18
- CLLS N/A
- EPS
- ANTA 0.47
- CLLS N/A
- Revenue
- ANTA $65,033,103.00
- CLLS $82,551,000.00
- Revenue This Year
- ANTA $65.94
- CLLS N/A
- Revenue Next Year
- ANTA $59.39
- CLLS $58.00
- P/E Ratio
- ANTA $20.13
- CLLS N/A
- Revenue Growth
- ANTA 63.28
- CLLS 129.04
- 52 Week Low
- ANTA $9.03
- CLLS $1.10
- 52 Week High
- ANTA $27.72
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- ANTA N/A
- CLLS 62.28
- Support Level
- ANTA N/A
- CLLS $3.49
- Resistance Level
- ANTA N/A
- CLLS $4.28
- Average True Range (ATR)
- ANTA 0.00
- CLLS 0.23
- MACD
- ANTA 0.00
- CLLS 0.07
- Stochastic Oscillator
- ANTA 0.00
- CLLS 83.69
About ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.